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Background/Aims: Studies have reported higher prevalences of four behavioral addictions (binge eating, compulsive
shopping, hypersexuality, and pathological gambling) in dopamine agonist-treated Parkinson’s disease relative to
non-dopamine agonist-treated Parkinson’s. However, recent case-control and epidemiological studies suggest that
prevalences of behavioral addictions in dopamine agonist-treated Parkinson’s may be similar to background popula-
tion rates. This study tests that hypothesis by examining the FDA Adverse Event Reporting System (FAERS) for evi-
dence of these associations, taking into account the potential impact of publicity on reporting rates. Methods: FAERS
reports in 2004 (pre-publicity for all but pathological gambling) and 2007 (post-publicity for all four behaviors) were
analyzed. A threshold consisting of ³3 cases, proportional reporting ratio ³2, and c2 with Yates’ correction ³4 was
used to detect signals (drug-associated adverse reactions) involving any of five dopamine agonists and any of four
behavioral addictions. Results: No reports containing compulsive shopping and no signal for binge eating and dopa-
mine agonists were found in either year. A weak signal was found for hypersexuality in 2004, with a stronger signal
in 2007. A robust signal was found for pathological gambling in 2004, with a more robust signal in 2007. Discus-
sion/Conclusions: These results suggest that publicity may increase reporting rates in the FAERS. Findings for binge
eating, compulsive shopping, and hypersexuality suggest that prevalences of these behaviors among those treated
with dopamine agonists may be similar to background population rates and thus may not reflect an adverse safety sig-
nal. Further investigation of the relationship between dopamine agonists and behavioral addictions is warranted.
Keywords: behavioral addictions, impulse control disorders, Parkinson’s disease, dopamine agonists, pharmaco-
vigilance, FAERS
INTRODUCTION
Since the 1960s, the US Food and Drug Administration
(FDA) has maintained a database, now called the FDA Ad-
verse Event Reporting System (FAERS), containing re-
ported adverse drug reactions (ADRs). As part of the FDA’s
post-market drug safety surveillance program, the database
is monitored for as yet unsuspected drug/ADR associations.
The myriad strengths of spontaneous reporting systems like
the FAERS have led to their becoming the mainstay of
pharmacovigilance programs, but their limitations are also
well recognized (Härmark & Van Grootheest, 2008;
Stephenson & Hauben, 2007). Strengths include cost-effec-
tiveness, as well as database structures intended to “cast a
wide net”. For example, those submitting reports to the
FAERS are encouraged to report all drugs they were taking
at the time of the ADR, as well as all phenomena that could
have been ADRs. Also, while it is possible to designate any
single drug in an FAERS report as the “primary suspect”,
there is no way to designate any single ADR as the catalyst
for the report. Moreover, in the interest of limiting barriers to
reporting, a report can be submitted by any individual or en-
tity – healthcare providers, patients, caregivers, legal profes-
sionals, pharmaceutical companies, etc. However, this fea-
ture also gives rise to one of FAERS’ limitations – since any-
one can submit a report, there are no formal criteria qualify-
ing the information submitted, so accuracy, quality, and
completeness vary (Stephenson & Hauben, 2007). The
FAERS is also limited in that it measures only the frequency
of reporting (i.e., it cannot be used to estimate incidence or
prevalence of ADRs), and outside factors such as “dear
healthcare provider” letters and publicity have been found to
influence reporting rates (Bate & Evans, 2009; Moore et al.,
2003).
The first English-language report to suggest a link be-
tween the dopamine agonist (DA) pramipexole [used to treat
Parkinson’s disease (PD)] and an impulse control disorder
[in this case, pathological gambling (PG) – a condition now
classified as a non-substance or behavioral addiction] was
published in 2003 and received considerable publicity
(Driver-Dunckley, Samanta & Stacy, 2003). The authors
performed a retrospective database review for PG among
1,884 PD patients seen in a 12-month period at a PD re-
search center. They identified nine subjects, eight of whom
were taking pramipexole at the time of PG onset. The ninth
subject was taking pergolide, another DA. The authors did
not specify by which criteria PG diagnosis was made and did
not evaluate statistical significance.
Prior reports suggesting links between dopaminergic
treatment for PD and PG differed from the 2003 report in
that they did not receive publicity and either described hedo-
nistic homeostatic dysregulation, a neuropsychological be-
havioral condition associated with substance (primarily levo-
dopa) misuse and/or addiction (Giovannoni, O’Sullivan,
ISSN 2062-5871 © 2014 Akadémiai Kiadó, Budapest
Journal of Behavioral Addictions 3(1), pp. 21–26 (2014)
DOI: 10.1556/JBA.3.2014.1.3
* Corresponding author: Katherine E. Gendreau, MPH; E-mail:
katherine.gendreau@aya.yale.edu
FULL-LENGTH REPORT
Turner, Manson & Lees, 2000; Gschwandtner, Aston,
Renaud & Fuhr, 2001; Serrano-Dueñas, 2002); or the dopa-
minergic drug in question was levodopa (Cools, Barker,
Sahakian & Robbins, 2003; Molina et al., 2000).
In 2006, Szarfman, Doraiswamy, Tonning and Levine
reported results of their examination of FAERS data from its
inception through March 2005 for evidence of the associa-
tion reported by Driver-Dunckley et al. (2003). Szarfman
et al. (2006) found that 39 of 67 reports containing gambling
also contained the DA pramipexole. However, the authors
did not evaluate the potential effect of publicity resulting
from the 2003 report on the reporting rate.
Four studies linking PG and three additional behavioral
addictions to DA treatment were published and received
considerable publicity in 2005 and 2006. Two of these stud-
ies reported associations between pramipexole and PG, as
well as binge eating (BE), compulsive shopping (CS), and
hypersexuality (HS) (Dodd et al., 2005; Pontone, Williams,
Bassett & Marsh, 2006). The remaining two studies reported
associations between DAs in general (not just pramipexole)
and CS, HS, and PG (Voon et al., 2006; Weintraub et al.,
2006).
There are several factors to consider in the evaluation
of the reported associations. First, Dodd et al. (2005) de-
scribed a case series. Second, while the authors of the three
2006 studies [i.e., Pontone et al. (2006), Voon et al. (2006),
Weintraub et al. (2006)], as well as a large, multi-center, in-
ternational study in 2010 (Weintraub et al., 2010) conducted
cross-sectional trials in North America, utilized validated
screens and/or DSM-IV diagnostic criteria and provided sta-
tistical analyses, none of them compared prevalences of BE,
CS or HS among either DA-treated or non-DA-treated PD
patients to prevalences in the general population. While
prevalences found among selected cohorts are not directly
comparable to prevalences found in the general population,
it is interesting to note that when current prevalences (time
frames ranged from active to six months) of BE, CS, and HS
among non-DA-treated PD patients found in these four stud-
ies are compared to point prevalences reported in the general
population, the former appear to be lower than the latter
[1.7% vs. 6.6% (BE); from 0% to 2.9% vs. 5.8% (CS); and
from 0% to 1.7% vs. 5% (HS)], although prevalence esti-
mates for some of these conditions/behaviors (e.g., HS) have
not been well examined in large community samples. That
being said, point prevalences of BE, CS and HS among
DA-treated PD patients reported in these four studies appear
to be similar to those reported in the general population [5.6%
vs. 6.6% (BE); from 0.7% to 7.2% vs. 5.8% (CS); and from
4.4% to 6.3% vs. 5% (HS)] (Black, Kehrberg, Flumerfelt &
Schlosser, 1997; Grucza, Przybeck & Cloninger, 2007;
Koran, Faber, Aboujaoude, Large & Serpe 2006; Shaffer,
Hall & Vander Bilt, 1999). Additionally, none of these four
cross-sectional studies excluded those who had experienced
these conditions prior to PD onset. A history of behavioral
addictions prior to disease onset has been found to be associ-
ated with the presence of a behavioral addiction post-disease
onset (Evans, Strafella, Weintraub & Stacy, 2009), and
Weintraub et al. (2006) found that 36.4% of the active cases
identified in their study had experienced the same behav-
ioral addiction prior to PD onset.
These observations suggest the possibility of alternate
interpretations of the apparent elevation in the prevalences
of BE, CS, and HS in DA-treated PD patients. For example,
it is possible that the dopamine depletion characteristic of
PD could be accompanied by reduced frequencies of certain
behaviors in which dopamine plays a role, and DA therapy
brings the prevalences of these behaviors back to back-
ground rates. If this were the case, then while there could be
evidence of such associations in the FAERS post-media
coverage due to publicity-stimulated reporting, there might
be no evidence in the FAERS pre-media coverage. Given
that FAERS data dating back to 2004, i.e., before the associ-
ations between DAs and BE, CS, and HS (but not PG) were
reported and publicized, are publicly available on the FDA’s
website, these data provide an opportunity to test that hy-
pothesis. For this analysis, FAERS data were examined at
two time points, 2004 and 2007, for evidence of associations
between DAs and BE, CS, HS, and PG. Given the observa-
tions listed in the previous paragraph, we hypothesized that
there would be evidence of these associations in 2007,
post-publicity of potential adverse effects, and that, with the
exception of PG, such associations would be weaker or not
evident in 2004.
METHODS
Participants
The ADR and drug data used in this analysis were obtained
from the FDA’s FAERS database. FAERS data from Janu-
ary 1, 2004 through the most recently completed quarter are
available on the FDA’s website.
Procedure
Each report to the FAERS is reviewed and ADRs are
recoded for data entry using the standardized, or “pre-
ferred”, terms found in the Medical Dictionary for Regula-
tory Affairs (MedDRA). We did not find the preferred term
compulsive shopping or any relevant preferred terms (shop-
lifting was excluded) containing the text strings buy, shop,
or spend, so only three relevant preferred terms were se-
lected for this analysis: binge eating, hypersexuality, and
pathological gambling. For each of those three terms, a
group of clinically related preferred terms was also selected
(see Table 1). FAERS reports listing one of the following
five orally administered DAs – bromocriptine, cabergoline,
pergolide, pramipexole, and ropinirole – as well as one or
more of these preferred terms, were analyzed. The drugs
were captured by using searches for exact spelling text
strings for trade and generic names as well as for a variety of
close misspellings. All initial reports in 2004 (i.e., pre-pub-
licity for BE, CS, and HS, but post-publicity for PG) and
2007 (i.e., post-publicity for all four conditions/behaviors)
were considered regardless of categorization of DA as pri-
mary suspect. A one-year time-period was selected in each
case as there is only one year of FAERS data available prior
to 2005 and a comparable time-period was selected for com-
parison status post the 2005 and 2006 publications men-
tioned above. Given that there is no limit to the number of
follow-up reports allowed per initial report, nor to the fre-
quency of reporting the same ADR for the same person, fol-
low-up reports were excluded.
Measures and statistical analysis
The data analysis algorithm chosen was the proportional re-
porting ratio (PRR). The PRR compares the frequency with
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which a particular ADR is reported for individuals taking a
specific drug/type of drug to the frequency with which the
same ADR is reported for individuals taking any other drug.
It is computed as [a/(a + c)]/[b/(b + d)], where a is the num-
ber of exposed cases, b is the number of unexposed cases, c
is the number of exposed non-cases, and d is the number of
unexposed non-cases (Evans, Waller & Davis, 2001). It is
straightforward to perform and interpret, commonly used,
and is arguably more sensitive than other, more complex
data-mining algorithms (Hauben, Reich & Gerrits, 2006).
For this analysis, the threshold established by Evans et al.
(2001) of three or more cases, PRR of at least two, and a c2
with Yates’ correction of at least four was considered a sig-
nal suggesting a potential hazard warranting further investi-
gation – for example, review of the full reports, which could
contain comorbidities or other potentially responsible medi-
cations. Confidence intervals and p-values were also calcu-
lated. All statistical analyses were performed using SAS 9.2
(Cary, NC, USA).
Ethics
All authors conformed to the highest standards of ethical
conduct in the submission of accurate data, acknowledging
the work of others and divulging potential conflicts of inter-
est. As the study involved the use of publicly accessible,
de-identified data, signed informed consent was not neces-
sary for this study. Given the use of de-identified data, the
study is exempted from IRB review under federal regulation
45 CFR Part 46.101(b).
RESULTS
Results are summarized in Table 2. In 2004, i.e., pre-public-
ity for BE, CS, and HS, out of 251 reports containing BE,
none also contained a DA (PRR = 0; c2 = 0.4). We found no
reports containing ADRs that could be categorized as CS. Of
91 reports containing HS, four also contained at least one
DA (PRR = 10; c2 = 22.6); and of 33 reports containing PG,
28 also contained at least one DA (PRR = 1,201; c2 =
4,906.9).
In 2007, i.e., recent post-publicity for all four behavioral
addictions, of 328 reports containing BE, six also contained
at least one DA (PRR = 2; c2 = 2.0). Again, we found no re-
ports containing ADRs that could be categorized as CS. Of
95 reports containing HS, 30 also contained at least one DA
(PRR = 50; c2 = 943.8); and of 184 reports containing PG,
170 also contained at least one DA (PRR = 1,304; c2 =
16,752.8).
DISCUSSION
This analysis was undertaken based upon the following pre-
mises and hypotheses: 1) the FAERS captures unsuspected
drug/ADR associations; 2) publicity may increase ADR re-
porting rates. Based on these notions, detection of a strong
signal for DAs and PG in 2004, given that it was publicized
in 2003, was hypothesized; detection of an equally large or
stronger signal for DAs and PG in 2007 was also hypothe-
sized, given ongoing publicity. The results of this analysis
are consistent with these hypotheses. Based on observations
discussed above, it was also hypothesized that no or weak
signals would be detected for DAs and BE, CS and HS in
2004. The results of this analysis for BE, CS and HS are con-
sistent with this hypothesis, with no signal found for BE or
CS, and a weak signal found for HS. Finally, it was hypothe-
sized that, in the setting of increased publicity, signals would
be detected for DAs and BE, CS and HS in 2007. However,
while the results of this analysis for HS were consistent with
this hypothesis, signals worthy of further consideration were
not found for BE and CS in 2007.
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Table 1. Preferred terms (ADRs) included in analysis
Primary preferred term Clinically-related preferred term
Binge eating Eating disorder
Eating disorder symptom
Bulimia
Hypersexuality Excessive masturbation
Excessive sexual fantasies
Exhibitionism
High-risk sexual behavior
Libido increased
Sexual abuse
Sexual activity increased
Sexual offense
Pathological gambling Gambling
ADR = adverse drug reaction.
Note: We found no preferred terms in 2004 or 2007 that could be cat-
egorized as compulsive shopping.
Table 2. Frequencies and signal threshold criteria for behavioral addictions and dopamine agonists
in the FDA’s FAERS Database in 2004 and 2007
Adverse drug reaction 2004 2007
(N = 199,754) (N = 254,162)
DA No DA PRR 95% CI c2 DA No DA PRR 95% CI c2
(n = 927) (n = 198,827) (Yates’) (n = 2,345) (n = 251,817) (Yates’)
Binge eating 0 251 0 0.0–4.1 0.4* 6 322 2 0.8–4.6 2.0*
Compulsive shopping 0 0 – – – 0 0 – – –
Hypersexuality 4 87 10 3.1–27.8 22.6** 30 65 50 31.5–77.7 943.8**
Pathological gambling 28 5 1,201 443.5–3,534.8 4,906.9** 170 14 1,304 740.6–2,342.1 16,752.8**
FDA = Food & Drug Administration, FAERS = FDA Adverse Event Reporting System, DA = dopamine agonist, CI = confidence interval, PRR =
proportional reporting ratio.
Note: The minimum criteria for a signal are: three or more cases, PRR of two or more, and c2 with Yates’ correction of at least four. The crude PRR is
computed as [a/(a + c)]/[b/(b + d)], where a is the number of exposed cases, b is the number of unexposed cases, c is the number of exposed non-cases,
and d is the number of unexposed non-cases.
* Both Fisher’s exact and Yates’ corrected p-values > 0.1.
** Both Fisher’s exact and Yates’ corrected p-values < 0.001.
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Taken together with the prevalences found by Pontone
et al. (2006), Voon et al. (2006), and Weintraub et al. (2006,
2010), one possible interpretation of these results is twofold.
First, PD itself may confer decreased risks for the develop-
ment of behavioral addictions, and second, DA therapy may
bring the risks of developing these behaviors back up to
baseline population rates. If this were the case, drug-naïve
PD patients could be expected to develop these behaviors at
rates lower than those of the general population, and
DA-treated PD patients could be expected to develop these
behaviors at rates similar to those of the general population.
Consistent with this interpretation, neither de Chazeron
et al. (2011) nor Isaias et al. (2008) found a significant dif-
ference between frequencies of behavioral addictions in
treated PD patients relative to healthy comparison subjects
in their cross-sectional, case-control studies; but, apparently
inconsistent with this interpretation, neither Antonini et al.
(2011) nor Weintraub, Papay & Siderowf (2013) found a
significant difference between frequencies of behavioral ad-
dictions in newly diagnosed, drug-naïve PD patients relative
to healthy comparison subjects in their cross-sectional,
case-control studies.
However, dopamine depletion in PD is gradual, and
compensatory escalation in both dose and number of adjunc-
tive medications over time is typical. Perhaps the net effect
of escalation in dopaminergic therapy coupled with gradual
dopamine loss is behavioral addictions prevalences similar
to those in the general population. It is possible that the
newly diagnosed, drug-naïve patients had not yet experi-
enced sufficient dopamine loss to demonstrate depressed
prevalences of behavioral addictions. Several studies have
found longer disease duration to be associated with the pres-
ence of a behavioral addiction (Auyeung et al., 2011; Lee et
al., 2009, 2010; Lim et al., 2011; Tanaka, Wada-Isoe,
Nakashita, Yamamoto & Nakashima, 2013; Weintraub et
al., 2006). If, in addition to its impact on movement, dopa-
mine depletion is associated with a reduction in behavioral
addictions, then a DA-related rise in the frequencies of these
behaviors back to baseline population rates would not neces-
sarily reflect an adverse safety signal.
Alternatively, it is possible that the FAERS either does not
always capture unsuspected drug/ADR associations or that
there can be a delay between appearance of an association in
the general population and its appearance in the FAERS. In
2013, White, Tatonetti, Shah, Altman & Horvitz found evi-
dence of an adverse drug/drug interaction among millions of
anonymized search data from several search engines before it
became evident in the FAERS. In addition, many people may
not expect drug side effects to encompass changes in behav-
ior; this could lower – or potentially even eliminate, in the
case of CS – the reporting rates for these behavioral addic-
tions in conjunction with DAs. And while the reports contain-
ing BE and at least one DA did not reach the signal threshold
in either 2004 or 2007, the number of reports did rise in 2007.
In addition to these possibilities, other factors may influence
the emergence of behavioral addictions in PD. For example,
being unmarried and living in the United States versus Can-
ada were each associated with behavioral addictions in PD.
As such, factors unrelated to PD or its treatment may influ-
ence the emergence of behavioral addictions in PD and thus
confound attribution and reporting.
As was described earlier, the FAERS is designed to “cast
a wide net”. The current analysis maximized this design by
not restricting reports analyzed to those in which DAs were
categorized as the primary suspect, and by analyzing all ini-
tial reports, including those submitted by non-healthcare
professionals. Also, the preferred terms chosen for analysis
included not only those that were clearly clinically related,
but also those that were less clear (such as “sexual abuse”
and “sexual offense”), as well as those that were less specific
(such as “eating disorder”).
Further, the quantity portion (i.e., three or more cases) of
the threshold selected in the current study was originally
proposed in the context of ADRs with much lower back-
ground risks than BE, CS, HS, and PG [e.g., .00012% (toxic
epidermal necrolysis) or .0006% (agranulocytosis) versus
6.6% (BE), 5.8% (CS), 5% (HS) or 1.1% (PG) (Begaud,
Moride, Tubert-Bitter, Chaslerie & Haramburu, 1994; Black
et al., 1997; Grucza et al., 2007; Koran et al., 2006; Shaffer
et al., 1999)]. The probability of coincidental reports in-
creases as background risk increases (Begaud et al., 1994).
This could impact interpretation of the four 2004 reports
containing both HS and a DA as a signal worthy of further
investigation.
This analysis has several limitations. In addition to the
limitations of spontaneous reporting systems addressed
above, these databases may be subject to underreporting (it
is estimated that as few as 10% of ADRs are reported), and
the possibility exists that reported cases may be different
from unreported cases (Begaud et al., 1994). Additionally,
this analysis did not examine individual reports for potential
confounders such as comorbidities or other medications.
The threshold selected in the current study (three or more
cases, PRR of at least two, and a c2 with Yates’ correction
of at least four) also warrants consideration. While this
threshold has been established and used in prior studies
(Evans et al., 2001), the use of another threshold may have
yielded different results. Finally, follow-up reports were ex-
cluded based on the rationale that if both initial and one or
more follow-up reports included a DA and a behavioral ad-
diction, the frequency of behavioral addictions would be ar-
tificially inflated. However, to the extent that follow-up re-
ports included DAs/behavioral addictions for initial reports
that did not, those frequencies were not captured by this
analysis.
CONCLUSIONS
The findings of the current study are largely consistent with
the notion that increased publicity is associated with in-
creased reporting of behavioral addictions in PD in the
FAERS database. The absence of signals for DAs and BE or
CS, and, prior to publicity, only a weak signal for DAs and
HS, is consistent with the notion that prevalences of these
behavioral addictions among those treated with DAs may be
similar to background population rates and thus may not re-
flect an adverse safety signal. Further investigation of the re-
lationship between DAs and behavioral addictions in PD is
warranted in order to provide appropriate information to pa-
tients, care providers and policy makers.
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